S-16924, a novel, potential antipsychotic with marked serotonin(1A) agonist properties. IV. A drug discrimination comparison with clozapine

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 427-436

  Millan, Mark J ^a   Schreiber, Rudy ^a   Monneyron, Sabine ^a   Denorme, Brigitte ^a   Melon, Christophe ^a   Queriaux, Sophie ^a   Dekeyne, Anne ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1 (1,4 BENZODIOXAN 6 YL) 4 (2 INDANYLMETHYL)PIPERAZINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BENZODIOXOPYRROLIDINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; ECOPIPAM; EPLIVANSERIN; FANANSERIN; MUSCARINIC RECEPTOR BLOCKING AGENT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SCOPOLAMINE; SEROTONIN 1A AGONIST; SEROTONIN 2C ANTAGONIST; SERTINDOLE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY;

ADRENERGIC AGENTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISCRIMINATION LEARNING; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENERALIZATION, STIMULUS; LIGANDS; MALE; MUSCARINIC ANTAGONISTS; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SCOPOLAMINE; SEROTONIN AGONISTS;

EID: 0032917380     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Baldessarini EJ, Huston-Lyons D, Campbell A, Marsh E and Cohen BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 60:12-16.
2. Boer T, Berendsen H, Broekkamp CLE, Vrjimoed-de Vriès MC, Vos RME, Tonnaer, JA and van Delft AML (1993) ORG-5222. Drugs Future 18:1117-1123.
3. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283: 1256-1263.
4. Bruhwyler J, Liégeois JF, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J and Céczy J (1997) JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties. Pharmacol Res 36:255-264.
5. Brunello N, Masotto C, Steardo L, Markstein R and Racagni, G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
6. Carey GJ and Bergman J (1997) Discriminative-stimulus effects of clozapine in squirrel monkeys: Comparison with conventional and novel antipsychotic drugs. Psychopharmacology 132:261-269.
7. Christoffersen CT and Meltzer LT (1998) Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 18:399-402.
8. Cunningham-Owens DC (1996) Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 51:895-930.
9. 2 receptor antagonist. Br J Pharmacol 105:27-36.
10. Ellenbroek BA, Lubbers LJ and Cools AR (1996) Activity of "seroquel" (ICI204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine. Neuropsychopharmacology 15:406-416.
11. Goudie AJ, Smith JA, Taylor A, Taylor MAI and Trinklebaok MD (1998) Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: Tests with subtype selective receptors ligands. Behav Pharmacol 9:699-710.
12. Goudie AJ and Taylor A (1998) Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 135:392-400.
13. 2 receptors. J Pharmacol Exp Ther 263:276-284.
14. Josselin SA, Miller R and Beninger RJ (1997) Behavioural effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 21:531-558.
15. Kahn RS and Davis KL (1995) New developments in dopamine and schizophrenia, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1215-1228, Raven Press, New York.
16. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
17. Keks NA (1996) Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 94:18-24.
18. Kelley BM and Porter JH (1997) The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707-719.
19. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427-434.
20. Knable MB and Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11:123-131.
21. 3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
22. Meltzer HY (1995) Atypical antipsychotic drugs, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1277-1286. Raven Press, New York.
23. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955.
24. 1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355.
25. 4 receptors: an in vitro and in vivo comparison to L-745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 287: 167-186.
26. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
27. 1A agonist properties. II: Functional profile in comparison to clozapine and haloperidol J Pharmacol Exp Ther 286: 1356-1373.
28. Moore NA, Tye NC, Axton MS and Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551.
29. 1A receptors. Neuropharmacology 35:119-121.
30. Nielsen EB (1988) Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94:115-118.
31. 2 antagonist, raclopride, discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294.
32. Porter JH and Strong SE (1996) Discriminative stimulus control with olanzapine: Generalization to the atypical antipsychotic clozapine. Psychopharmacology 128: 216-219.
33. 2 receptor antagonist. J Pharmacol Exp Ther 262:759-768.
34. Roth BL and Meltzer HY (1995) The role of serotonin in schizophrenia, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1215-1228, Raven Press, New York.
35. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembøl HL, Meier E, Perregaard J and Skarsfeldt T (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250.
36. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
37. Schreiber R, Brocco M and Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL100,907 and the "atypical" antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99-102.
38. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA and Heym J (1995) Ziprasidone (CP88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113.
39. 4 receptors. Neuropsychopharmacology 16:93-135.
40. Tang AH, Franklin SR, Himes CS, Smith MW and Tenbrink RE (1997) PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther 281:440-447.
41. Wiley JL and Porter JH (1992) Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Behav 43:961-965.
42. Wirsching WC, Marder SR, Van Putten T and Ames D (1995) Acute treatment of schizophrenia, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1259-1266, Raven Press, New York.